The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Multiple pregnancy (MP) is associated with significant fetomaternal complications and a high cost. The multiple pregnancy rate per cycle (MPR) of treatment with Assisted Reproductive Technology (ART) is 25 % or higher even in countries where ART is reimbursed, much higher than the 1% after natural conception, related to the number of embryos transferred, and preventable by single embryo transfer (SET). In Belgium, the laboratory costs for 6 fresh ART cycles are reimbursed for female patients younger than 43 with a Belgian insurance number since July 2003, but only if a limited number of embryos is transferred depending on female age and cycle rank. Although this policy has resulted in a significant reduction in the MPR after ART in Belgium from 24 % to 13 %, available data are cycle based and it is unknown if the cumulative delivery rate per patient is affected by this legislation. The aim of this study was to test the hypothesis that Belgian ART legislation since 2003, coupling lab reimbursement to restriced embryo transfer policy, has resulted in a reduced CDR when compared to the situation before 2003.
| Condition |
|---|
|
Impact of Legislation on Cumulative Delivery Rate |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
- cumulative delivery rate [ Time Frame: 1999-2006 ] [ Designated as safety issue: Yes ]
| Enrollment: | 1258 |
| Study Start Date: | September 2010 |
| Study Completion Date: | July 2012 |
| Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
after legislation 1st july 2003
2003-2006
|
|
before legislation 1st july 2003
1999-2003
|
Eligibility| Ages Eligible for Study: | 18 Years to 43 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
patients undergoing IVF/ICSI cycles
Inclusion Criteria:
- patients with their first IVF/ICSI cycle
Exclusion Criteria:
- cycles without oocytes or sperm, oocyte reception cycles, embryo reception cycles, cycles with preimplantation genetic diagnosis/screening
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Sophie Debrock, Prof. Dr, Katholieke Universiteit Leuven |
| ClinicalTrials.gov Identifier: | NCT01720134 History of Changes |
| Other Study ID Numbers: | S53562 |
| Study First Received: | October 25, 2012 |
| Last Updated: | October 31, 2012 |
| Health Authority: | Belgium: |
ClinicalTrials.gov processed this record on May 16, 2013